These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16842160)

  • 1. Regulation of angiogenesis by the kallikrein-kinin system.
    Colman RW
    Curr Pharm Des; 2006; 12(21):2599-607. PubMed ID: 16842160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen.
    Colman RW; Pixley RA; Sainz IM; Song JS; Isordia-Salas I; Muhamed SN; Powell JA; Mousa SA
    J Thromb Haemost; 2003 Jan; 1(1):164-70. PubMed ID: 12871554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contact system and angiogenesis: potential for therapeutic control of malignancy.
    Colman RW
    Semin Thromb Hemost; 2004 Feb; 30(1):45-61. PubMed ID: 15034797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two faces of high-molecular-weight kininogen (HK) in angiogenesis: bradykinin turns it on and cleaved HK (HKa) turns it off.
    Guo YL; Colman RW
    J Thromb Haemost; 2005 Apr; 3(4):670-6. PubMed ID: 15733059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inhibition of tube formation in a collagen-fibrinogen, three-dimensional gel by cleaved kininogen (HKa) and HK domain 5 (D5) is dependent on Src family kinases.
    Liu Y; Sainz IM; Wu Y; Pixley R; Espinola RG; Hassan S; Khan MM; Colman RW
    Exp Cell Res; 2008 Feb; 314(4):774-88. PubMed ID: 18062965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of angiogenesis by cleaved high molecular weight kininogen (HKa) and HKa domain 5.
    McCrae KR; Doñate F; Merkulov S; Sun D; Qi X; Shaw DE
    Curr Cancer Drug Targets; 2005 Nov; 5(7):519-28. PubMed ID: 16305348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of angiogenesis by a monoclonal antibody to kininogen as well as by kininostatin which block proangiogenic high molecular weight kininogen.
    Colman RW
    Int Immunopharmacol; 2002 Dec; 2(13-14):1887-94. PubMed ID: 12489802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kininostatin as an antiangiogenic inhibitor: what we know and what we do not know.
    Guo YL; Wang S; Colman RW
    Int Immunopharmacol; 2002 Dec; 2(13-14):1931-40. PubMed ID: 12489806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis.
    Colman RW; Jameson BA; Lin Y; Johnson D; Mousa SA
    Blood; 2000 Jan; 95(2):543-50. PubMed ID: 10627460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [High molecular weight kininogen in inflammation and angiogenesis: a review of its properties and therapeutic applications].
    Isordia-Salas I; Sainz IM; Pixley RA; Martínez-Murillo C; Colman RW
    Rev Invest Clin; 2005; 57(6):802-13. PubMed ID: 16708906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial-cell apoptosis induced by cleaved high-molecular-weight kininogen (HKa) is matrix dependent and requires the generation of reactive oxygen species.
    Sun D; McCrae KR
    Blood; 2006 Jun; 107(12):4714-20. PubMed ID: 16418331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions.
    Chavakis T; Kanse SM; Lupu F; Hammes HP; Müller-Esterl W; Pixley RA; Colman RW; Preissner KT
    Blood; 2000 Jul; 96(2):514-22. PubMed ID: 10887113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Domain 5 of cleaved high molecular weight kininogen inhibits endothelial cell migration through Akt.
    Katkade V; Soyombo AA; Isordia-Salas I; Bradford HN; Gaughan JP; Colman RW; Panetti TS
    Thromb Haemost; 2005 Sep; 94(3):606-14. PubMed ID: 16268479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway.
    Liu Y; Pixley R; Fusaro M; Godoy G; Kim E; Bromberg ME; Colman RW
    Oncogene; 2009 Jul; 28(30):2756-65. PubMed ID: 19483730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urokinase-type plasminogen activator receptor is involved in mediating the apoptotic effect of cleaved high molecular weight kininogen in human endothelial cells.
    Cao DJ; Guo YL; Colman RW
    Circ Res; 2004 May; 94(9):1227-34. PubMed ID: 15044324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple myeloma in a murine syngeneic model:modulation of growth and angiogenesis by a monoclonal antibody to kininogen.
    Sainz IM; Isordia-Salas I; Espinola RG; Long WK; Pixley RA; Colman RW
    Cancer Immunol Immunother; 2006 Jul; 55(7):797-807. PubMed ID: 16187087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the light chain of high molecular weight kininogen in adhesion, cell-associated proteolysis and angiogenesis.
    Colman RW
    Biol Chem; 2001 Jan; 382(1):65-70. PubMed ID: 11258675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of leukocyte recruitment by polypeptides derived from high molecular weight kininogen.
    Chavakis T; Kanse SM; Pixley RA; May AE; Isordia-Salas I; Colman RW; Preissner KT
    FASEB J; 2001 Nov; 15(13):2365-76. PubMed ID: 11689462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptotic effect of cleaved high molecular weight kininogen is regulated by extracellular matrix proteins.
    Guo YL; Wang S; Cao DJ; Colman RW
    J Cell Biochem; 2003 Jun; 89(3):622-32. PubMed ID: 12761895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of metastasis of syngeneic murine melanoma in vivo and vasculogenesis in vitro by monoclonal antibody C11C1 targeted to domain 5 of high molecular weight kininogen.
    Khan ST; Pixley RA; Liu Y; Bakdash N; Gordon B; Agelan A; Huang Y; Achary MP; Colman RW
    Cancer Immunol Immunother; 2010 Dec; 59(12):1885-93. PubMed ID: 20811885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.